Remuneration for non-interventional studies – results of a survey in the pharmaceutical industry in Germany

In 2007 the Association of Research-Based Pharmaceutical Companies (vfa) published recommendations to improve the quality and transparency of non-interventional studies. These recommendations include quality assurance measures, in particular with respect to transparency as well as for the verification of the data collected in these studies. This publication presents the results of a survey on fees in non-interventional studies which was conducted within the member companies of the vfa in June 2011. These results demonstrate a consistent adherence to the statutory requirements and the implementation of the recommendations concerning the remuneration of the study centers. Depending on the indication, the number of routine doctor/patient contacts is different and associated with that number the documentation efforts vary. Accordingly, the fee varies based on the fee schedule for physicians (German: Gebührenordnung für Ärzte) by taking into account the actual efforts at the study center

Remuneration for non-interventional studies – results of a survey in the pharmaceutical industry in Germany

In 2007 the Association of Research-Based Pharmaceutical Companies (vfa) published recommendations to improve the quality and transparency of non-interventional studies. These recommendations include quality assurance measures, in particular with respect to transparency as well as for the verification of the data collected in these studies. This publication presents the results of a survey on fees in non-interventional studies which was conducted within the member companies of the vfa in June 2011. These results demonstrate a consistent adherence to the statutory requirements and the implementation of the recommendations concerning the remuneration of the study centers. Depending on the indication, the number of routine doctor/patient contacts is different and associated with that number the documentation efforts vary. Accordingly, the fee varies based on the fee schedule for physicians (German: Gebührenordnung für Ärzte) by taking into account the actual efforts at the study center

Fluorescence calorimetry of an ion crystal

Motivated by the challenge of identifying intruder ions in a cold ion crystal, we investigate calorimetry from emitted fluorescence light. Under continuous Doppler cooling, the ion crystal reaches a temperature equilibrium with a fixed level of fluorescence intensity and any change in the motional energy of the crystal results in a modification of this intensity. We theoretically determine the fluorescence rate of an ion crystal as a function of the temperature, assuming that laser light is scattered along a two-level electronic transition, which couples to the crystal's vibrations via the mechanical effects of light. We analyse how the heat dissipated by collisions of an incoming intruder ion alters the scattering rate. We argue that an energy change by an incoming $^{229}$Th$^{10+}$ can be unambiguously detected within 50\,$\mu$s via illuminating 50 ions out of a 10$^{3}$ ion crystal. This method enables applications including capture and spectroscopy of charged states of thorium isotopes and investigation of highly charged ions.Comment: 10 pages, 5 figure

Cytotoxicity screening of 23 engineered nanomaterials using a test matrix of ten cell lines and three different assays

<p>Abstract</p> <p>Background</p> <p>Engineered nanomaterials display unique properties that may have impact on human health, and thus require a reliable evaluation of their potential toxicity. Here, we performed a standardized <it>in vitro </it>screening of 23 engineered nanomaterials. We thoroughly characterized the physicochemical properties of the nanomaterials and adapted three classical <it>in vitro </it>toxicity assays to eliminate nanomaterial interference. Nanomaterial toxicity was assessed in ten representative cell lines.</p> <p>Results</p> <p>Six nanomaterials induced oxidative cell stress while only a single nanomaterial reduced cellular metabolic activity and none of the particles affected cell viability. Results from heterogeneous and chemically identical particles suggested that surface chemistry, surface coating and chemical composition are likely determinants of nanomaterial toxicity. Individual cell lines differed significantly in their response, dependent on the particle type and the toxicity endpoint measured.</p> <p>Conclusion</p> <p><it>In vitro </it>toxicity of the analyzed engineered nanomaterials cannot be attributed to a defined physicochemical property. Therefore, the accurate identification of nanomaterial cytotoxicity requires a matrix based on a set of sensitive cell lines and <it>in vitro </it>assays measuring different cytotoxicity endpoints.</p

Gelingendes Leben - Krise als Chance für Person & Gesellschaft. Band II

• Peter Antes, Rel.wiss. • Petra Bahr, Theol. / Journ. • Matthias Beck Med./JS, AT • Gottfried Biewer, Bildungswiss., AT • Aladin El-Mafaalani, Pol.wiss.• Johannes Eurich, Diak.wiss. • Mario Feigel, Med. CH • Heike Gramkow, Manag.Dir. • Heinrich Greving, Heilpäd. • Udo Hahn, Theol.• Maria-C. Hallwachs, Stud., Beratg. schon betroffen • Walter Hirche, Min. a.D./Präs. Dt. UNESCO • Wolfgang Jantzen †, Soz. • Jochen-C. Kaiser, Hist. • Karl-J. Kemmelmeyer, Präs. Musikrat • Hermes Kick, Med.-Ethik • Waldemar Kippes Redemptorist JN • Ferdinand Klein, SoPäd., SK • Berthold Krüger, bpb • Christian Larsen, Arzt, CH • Ulrich Lilie Präs. Diak.W • Christian Lindmeier, SoPäd., DGfE • Ralf Meister, Bischof • Bertolt Meyer, Org.- u. Wirtschaftspsych, schon betroffen, CH • Peter Neher, Präs. Caritas • Ekkehard Nuissl, Dir. Dt. Inst. EB, DIE • Ulrich Pohl, Vorst. Bethel • Hartmann Römer, Physiker • David Roth, Lt. Hospiz • Hartmut Schlegel SoPäd. • Joachim Schoss, Unternehmer, schon betroffen, CH • Walter Surböck Med., AT• Karl-H. Steinmetz, Trad. Europ. Med., AT • Rudolf Tippelt, Bildg. Forschg. • Inge Wasserberg, Inklu.Beratg. • Walter Thirring †, Phys. CERN, C

Why Are Outcomes Different for Registry Patients Enrolled Prospectively and Retrospectively? Insights from the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF).

Background: Retrospective and prospective observational studies are designed to reflect real-world evidence on clinical practice, but can yield conflicting results. The GARFIELD-AF Registry includes both methods of enrolment and allows analysis of differences in patient characteristics and outcomes that may result. Methods and Results: Patients with atrial fibrillation (AF) and ≥1 risk factor for stroke at diagnosis of AF were recruited either retrospectively (n = 5069) or prospectively (n = 5501) from 19 countries and then followed prospectively. The retrospectively enrolled cohort comprised patients with established AF (for a least 6, and up to 24 months before enrolment), who were identified retrospectively (and baseline and partial follow-up data were collected from the emedical records) and then followed prospectively between 0-18 months (such that the total time of follow-up was 24 months; data collection Dec-2009 and Oct-2010). In the prospectively enrolled cohort, patients with newly diagnosed AF (≤6 weeks after diagnosis) were recruited between Mar-2010 and Oct-2011 and were followed for 24 months after enrolment. Differences between the cohorts were observed in clinical characteristics, including type of AF, stroke prevention strategies, and event rates. More patients in the retrospectively identified cohort received vitamin K antagonists (62.1% vs. 53.2%) and fewer received non-vitamin K oral anticoagulants (1.8% vs . 4.2%). All-cause mortality rates per 100 person-years during the prospective follow-up (starting the first study visit up to 1 year) were significantly lower in the retrospective than prospectively identified cohort (3.04 [95% CI 2.51 to 3.67] vs . 4.05 [95% CI 3.53 to 4.63]; p = 0.016). Conclusions: Interpretations of data from registries that aim to evaluate the characteristics and outcomes of patients with AF must take account of differences in registry design and the impact of recall bias and survivorship bias that is incurred with retrospective enrolment. Clinical Trial Registration: - URL: http://www.clinicaltrials.gov . Unique identifier for GARFIELD-AF (NCT01090362)

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362